Compare ESOA & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESOA | FHTX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 314.2M | 323.4M |
| IPO Year | 2006 | 2020 |
| Metric | ESOA | FHTX |
|---|---|---|
| Price | $17.94 | $4.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $21.00 | $11.50 |
| AVG Volume (30 Days) | 91.7K | ★ 106.8K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $122,465,826.00 | $30,909,000.00 |
| Revenue This Year | $9.22 | $8.89 |
| Revenue Next Year | $3.77 | $20.13 |
| P/E Ratio | $107.00 | ★ N/A |
| Revenue Growth | 2.74 | ★ 36.75 |
| 52 Week Low | $7.84 | $3.27 |
| 52 Week High | $17.25 | $6.95 |
| Indicator | ESOA | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 72.80 | 40.62 |
| Support Level | $12.65 | $4.44 |
| Resistance Level | N/A | $4.69 |
| Average True Range (ATR) | 0.80 | 0.27 |
| MACD | 0.19 | -0.05 |
| Stochastic Oscillator | 91.99 | 4.17 |
Energy Services of America Corporation is engaged in providing contracting services for energy-related companies. The company is predominantly engaged in the construction, replacement, and repair of natural gas pipelines and storage facilities for utility companies and private natural gas companies. It services the gas, petroleum, power, chemical, and automotive industries and does incidental work such as water and sewer projects. Energy Service's other services include liquid pipeline construction, pump station construction, production facility construction, water and sewer pipeline installations, various maintenance and repair services, and other services related to pipeline construction.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.